Who is sponsoring NCT05360901?

NCT05360901 is sponsored by Brigham and Women's Hospital.

What drugs are being tested in NCT05360901?

Interventions in NCT05360901: IntelliCare with automated motivational messaging.

What condition does NCT05360901 study?

NCT05360901 studies Depression, Anxiety.

Is NCT05360901 still recruiting?

NCT05360901 is currently completed. Last updated 18 December 2023.

Are results published for NCT05360901?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2023-12-18 · How we verify

NCT05360901

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Toward Understanding Drivers of Patient Engagement With Digital Mental Health Interventions - Part I

Completed NA Results posted Last updated 18 December 2023

What this trial tests

NA trial testing IntelliCare with automated motivational messaging in Depression, Anxiety in 12 participants. Completed in 17 October 2022.

Timeline

6 July 2022

Primary endpoint
17 October 2022

17 October 2022

Quick facts

Lead sponsor	Brigham and Women's Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	12
Start date	6 July 2022
Primary completion	17 October 2022
Estimated completion	17 October 2022
Sites	1 location across United States

Drugs / interventions tested

IntelliCare with automated motivational messaging

Conditions studied

Depression, Anxiety — all drugs for Depression, Anxiety →

Sponsor

Brigham and Women's Hospital

Who can join

Adults 18 to 80, any sex, with Depression, Anxiety. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Message Motivation Ratings Primary · 24 hours from message delivery

Mean Likert scale rating of how well participants felt each message motivated them to use the digital mental health intervention as rated within 24 hours of message delivery. The Likert scale will range from 1 (not at all motivating) to 10 (very motivating) with a score of 5 being neutral.

Group	Value	95% CI
IntelliCare With Automated Motivational Messaging	6.33	± 2.02

Message Likability Ratings Secondary · 24 hours from message delivery

Mean Likert scale rating of how much participants liked each message as rated within 24 hours of message delivery. The Likert scale will range from 1 (hated the message) to 10 (loved the message) with a score of 5 being neutral.

Group	Value	95% CI
IntelliCare With Automated Motivational Messaging	6.35	± 1.95

Engagement Secondary · 3 hours from message delivery

Percent of instances of message delivery that prompted user to launch the digital mental health intervention within 3 hours of delivery.

Group	Value	95% CI
IntelliCare With Automated Motivational Messaging	23.84	± 21.51

Sponsor's own description

This pilot study is a precursor to a subsequent clinical trial that will test the impact of a set of automated motivational messages on patient engagement with a digital mental health intervention. The pilot study aims to systematically employ patient feedback to develop the automated motivational messages that will be used in the subsequent clinical trial.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Depression, Anxiety

Currently open trials in the same condition.

NCT07278466 — The COMParing App Support Strategies Study · NA · recruiting
NCT07280481 — Weekly Dynamics of Psychopathological and Symptom Networks During Mindfulness-Based Interventions for Emotional Distress · NA · recruiting
NCT07014852 — Integrating Inuit Knowledge Principles in Multi-Level Mental Health Clinical Trials · EARLY_PHASE1 · recruiting
NCT07186816 — SUpport From PEeRs to Expand Access Study - Community · NA · recruiting
NCT07091032 — Building Connections · NA · recruiting

Other Brigham and Women's Hospital trials

Trials by the same sponsor.

NCT07011758 — Dynamic Treatment Regimes for Opioid Use Disorder · Phase 2 · not yet recruiting
NCT06310018 — Augmented Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for PE · suspended
NCT04519177 — Randomized Trial of a Sleep Disorders Program on Firefighter Safety and Disability ... · NA · not yet recruiting
NCT06355986 — Computerized Decision Support to Prevent Stroke in Atrial Fibrillation · NA · not yet recruiting
NCT06099275 — Evaluation of Hemodynamics in People With Untreated Preeclampsia Using Echocardiography · suspended

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05360901 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Brigham and Women's Hospital
Last refreshed: 18 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05360901.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing